A Phase 2 interventional study of Pimavanserin in Treatment of Depression in Adults With Parkinson's Disease (PD), sponsored by ACADIA Pharmaceuticals Inc.. Completed at 21 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-08-31.
Sponsored by ACADIA Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,715 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.
Among the 3,715 studies in Depression with a site in United States, this one is the 2,067th largest by enrollment of the 3,322 interventional ones that give a count, is one of 164 that started in 2018, is one of 337 in phase 2, and was the 1,977th registered.
8,595 studies on the registry are indexed under Depression; 1,735 are open to participants now.
Browse Depression studies →582 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 13+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger; 206 take children under 18; 314 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 164 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 81 across 7,083 interventional studies indexed under Depression.
Median enrollment 72 across the 3,322 interventional studies, 138 across the 371 observational. Of the 2,764 that completed or were terminated, 1,045 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,715 have an industry lead sponsor. The 10 most frequent:
ACADIA Pharmaceuticals Inc. is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 24 (92%) have results posted.
ACADIA Pharmaceuticals Inc. has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
300 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 300 to your calendar (.ics) → With an account.
Among the 3,715 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year, defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features:
Exclusion Criteria:
Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimavanserin
Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
Change From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.
Time frame: From baseline to Week 8
Change From Baseline (CFB) in HAMD-17 Total Score at Weeks 2, 4, and 6
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.
Time frame: 2, 4, and 6 weeks from baseline
Clinical Global Impression-Improvement (CGI-I)
The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse)
Time frame: At Week 8
Change From Baseline (CFB) in Clinical Global Impression-Severity (CGI-S)
The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill).
Time frame: From baseline to Week 8
Change From Baseline (CFB) in Scale of Outcomes in PD-Sleep Scale (SCOPA) Nighttime Sleep (NS)Score
The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems.
Time frame: From baseline to Week 8
Change From Baseline (CFB) in SCOPA Daytime Sleepiness (DS) Score
The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems.
Time frame: From baseline to Week 8
The Number (or Percentage) of Responders
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression. Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders.
Time frame: From baseline to Week 8
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine).
Time frame: From baseline to Week 8
| Milestone | Pimavanserin |
|---|---|
| Started | 47 |
| Completed | 40 |
| Not completed | 7 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Not further specified | 1 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline HAMD-17 total score | 19.2 ± 0.46 |
| Week 8 HAMD-17 total score | 8.1 ± 0.77 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline HAMD-17 total score | 19.2 ± 0.46 |
| Week 2 HAMD-17 total score CFB | -7.5 ± 0.89 |
| Week 4 HAMD-17 total score CFB | -9.7 ± 0.69 |
| Week 6 HAMD-17 total score CFB | -9.6 ± 0.69 |
The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse)
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Clinical Global Impression-Improvement (CGI-I) | 2.0 ± 0.16 |
The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill).
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline CGI-S | 4.1 ± 0.08 |
| 8 Week CGI-S CFB | -1.8 ± 0.17 |
The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems.
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline SCOPA-NS | 6.1 ± 0.51 |
| Week 8 SCOPA-NS CFB | -2.1 ± 0.57 |
The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems.
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline SCOPA-DS | 5.2 ± 0.56 |
| 8 Week SCOPA-DS CFB | -2.2 ± 0.50 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression. Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders.
| Participants | Pimavanserin Full Analysis Set |
|---|---|
| The Number (or Percentage) of Responders | 27 |
The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine).
| score on a scale | Pimavanserin Full Analysis Set |
|---|---|
| Baseline EQ-5D-5L index score | 0.6750 ± 0.02551 |
| 8 Week EQ-5D-5L index score CFB | 0.0712 ± 0.02629 |
| Baseline EQ-5D-5L VAS | 63.9 ± 2.43 |
| 8 Week EQ-5D-5L VAS CFB | 6.7 ± 2.61 |
Collected over From the time of informed consent through a safety follow-up visit at Week 10. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pimavanserin | 0/47 (0%) | 1/47 (2.1%) | 21/47 (44.7%) |
| Event | Pimavanserin |
|---|---|
| ColitisGastrointestinal disorders | 1/47 |
| Event | Pimavanserin |
|---|---|
| FallInjury, poisoning and procedural complications | 4/47 |
| NauseaGastrointestinal disorders | 3/47 |
| DiarrhoeaGastrointestinal disorders | 2/47 |
| OedemaGeneral disorders | 2/47 |
| Urinary tract infectionInfections and infestations | 2/47 |
| Skin abrasionInjury, poisoning and procedural complications | 2/47 |
| Abdominal painGastrointestinal disorders | 1/47 |
| ConstipationGastrointestinal disorders | 1/47 |
| GastritisGastrointestinal disorders | 1/47 |
| VomitingGastrointestinal disorders | 1/47 |
Patients treated with study drug
| Age, Continuous(years) | Pimavanserin Safety Analysis Set |
|---|---|
| Mean | 69.6 ± 8.25 |
| Sex: Female, Male(Participants) | Pimavanserin Safety Analysis Set |
|---|---|
| Female | 23 |
| Male | 24 |
| Race (NIH/OMB)(Participants) | Pimavanserin Safety Analysis Set |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 43 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Pimavanserin Safety Analysis Set |
|---|---|
| United States | 47 |
| Duration of Parkinson's Disease (PD)(years) | Pimavanserin Safety Analysis Set |
|---|---|
| Mean | 7.8 ± 5.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Jul 2019, 16 months.
Results were first posted in Aug 2020, 1 year 1 month after primary completion.
Of 53 industry-sponsored phase 2 interventional studies under Depression, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 29. This study's 16 months is close to that.
Counting every sponsor, half of 197 studies reached it within 31 months; a quarter within 18 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimavanserin